This article is more than 6 months old
Alyftrek available in Northern Ireland and Wales
Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) is a new once-a-day triple combination modulator drug. It provides a treatment option for some people with cystic fibrosis who are not eligible or able to take Kaftrio and an alternative for people who are already taking Kaftrio.
Read our FAQs to find out more
Please speak to your CF team for further information about your own treatment options.
This is an important moment for people with cystic fibrosis and it is thanks to years of campaigning that people in Wales and Northern Ireland have access to new treatments.
Dr Keith Brownlee, Cystic Fibrosis Trust Director of Medical Affairs
We must remember that these medicines are not a cure, and do not work for everyone. Cystic Fibrosis Trust will not stop until everyone with CF can live a life unlimited.
In Scotland, the Scottish Medicines Consortium (SMC) is assessing Alyftrek through a separate process. We continue to monitor progress and you can see direct updates from the SMC on their website.
In the meantime, the SMC also advised that, on a case by case basis, clinicians can use the peer approved clinical system (PACS) tier two process. This allows them to request Alyftrek if they believe it will have a large health benefit for someone with CF.